KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $52.0 million.

  • Moderna's Depreciation & Amortization (CF) changed 0.0% to $52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.0 million, marking a year-over-year decrease of 3716.01%. This contributed to the annual value of $189.0 million for FY2024, which is 6956.52% down from last year.
  • As of Q3 2025, Moderna's Depreciation & Amortization (CF) stood at $52.0 million, which was down 0.0% from $57.0 million recorded in Q2 2025.
  • Moderna's Depreciation & Amortization (CF)'s 5-year high stood at $249.0 million during Q3 2023, with a 5-year trough of $15.0 million in Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $80.9 million, with a median of $70.0 million in 2021.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 101428.57% in 2021, then plummeted by 7911.65% in 2024.
  • Over the past 5 years, Moderna's Depreciation & Amortization (CF) (Quarter) stood at $78.0 million in 2021, then rose by 2.56% to $80.0 million in 2022, then soared by 152.5% to $202.0 million in 2023, then tumbled by 70.3% to $60.0 million in 2024, then dropped by 13.33% to $52.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $52.0 million for Q3 2025, versus $57.0 million for Q2 2025 and $39.0 million for Q1 2025.